A detailed history of Credit Suisse Ag transactions in Savara Inc stock. As of the latest transaction made, Credit Suisse Ag holds 90,705 shares of SVRA stock, worth $297,512. This represents 0.0% of its overall portfolio holdings.

Number of Shares
90,705
Holding current value
$297,512
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$4.19 - $5.59 $380,053 - $507,040
90,705 New
90,705 $451,000
Q2 2022

Aug 12, 2022

BUY
$1.1 - $1.58 $2 - $3
2 New
2 $0
Q1 2021

May 14, 2021

SELL
$1.17 - $2.33 $16,069 - $32,002
-13,735 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$1.0 - $1.47 $13,735 - $20,190
13,735 New
13,735 $16,000
Q2 2019

Aug 14, 2019

SELL
$2.37 - $11.7 $24,297 - $119,948
-10,252 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$6.71 - $8.6 $68,790 - $88,167
10,252 New
10,252 $75,000

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $374M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.